Lupin receives EIR from US FDA for its Somerset manufacturing facility
The facility was inspected from May 7 to May 17, 2024
The facility was inspected from May 7 to May 17, 2024
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
The pilot plant is focused on scaling up beverage production and will support applications
The plant is yet to start commercial operations
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Subscribe To Our Newsletter & Stay Updated